Nexalin Technology Commences Sales Of Gen-2 Neurostimulation Device To New Mental Health Center In Oman Dedicated To Nexalin's Technology
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology, Inc. has started selling its Gen-2 neurostimulation device to a new mental health center in Oman, which focuses on treating substance abuse disorder with Nexalin's device. The center opened after receiving approval from Oman's Ministry of Health, highlighting the device's regulatory endorsement and its potential for broader mental health applications. Nexalin aims to change mental health treatment paradigms globally, emphasizing drug-free therapy without adverse side effects.
March 14, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nexalin Technology begins sales of its Gen-2 neurostimulation device in Oman, focusing on substance abuse disorders, with regulatory approval from Oman's Ministry of Health.
The commencement of sales in Oman, backed by regulatory approval, signifies a major milestone for Nexalin Technology. This development not only validates the company's technology but also opens up new market opportunities. The focus on a drug-free, side-effect-free treatment could position Nexalin favorably in the mental health treatment market, potentially boosting investor confidence and stock performance in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100